Pioglitazone, used for type 2 diabetes, belongs to which class of antidiabetic drugs?

• A. Thiazolidinedione
• B. Biguanide
• C. Sulfonylurea
• D. DPP-4 inhibitor

Answer: (D)

Pioglitazone belongs to the thiazolidinedione class. This group works as agonists of the nuclear receptor PPAR-γ, which changes the expression of genes involved in insulin sensitivity. By activating PPAR-γ in fat, muscle, and liver, thiazolidinediones improve how effectively the body responds to insulin, reducing insulin resistance and helping glucose be taken up and utilized more efficiently. That mechanism underpins its use in type 2 diabetes as an add-on therapy.

This differs from other antidiabetic classes. DPP-4 inhibitors, for example, increase incretin hormones to boost insulin secretion and suppress glucagon, which is not how pioglitazone works. Biguanides (like metformin) mainly reduce hepatic glucose production and improve insulin sensitivity, while sulfonylureas stimulate insulin release from pancreatic beta cells. Pioglitazone’s primary action is improving insulin sensitivity through PPAR-γ activation, not increasing insulin secretion or directly reducing hepatic glucose production.